Focused On-demand Library for Large ribosomal subunit protein eL21

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P46778

UPID:

RL21_HUMAN

Alternative names:

60S ribosomal protein L21

Alternative UPACC:

P46778; Q16699

Background:

The Large ribosomal subunit protein eL21, also known as 60S ribosomal protein L21, plays a crucial role in protein synthesis. As a component of the large ribosomal subunit, it is involved in the assembly and function of the ribosome, a complex essential for translating mRNA into proteins. This process is fundamental to all cellular operations and the maintenance of cellular health.

Therapeutic significance:

Given its pivotal role in protein synthesis, understanding the function of Large ribosomal subunit protein eL21 could open doors to potential therapeutic strategies, especially considering its link to Hypotrichosis 12. This condition, characterized by reduced hair density and fragile hair, underscores the protein's significance in cellular processes beyond protein synthesis, hinting at its potential in targeted therapy development.